Overview
Employees
51-200
Total raised
$10M
Founded date
1994
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 9, 2012 | Rival’s setback provides unexpected advantage for drug developer’s kidney injury therapeutic | Complexa CEO Joshua Tarnoff presented its kidney disease and kidney injury therapeutic at the Greater Philadelphia Alliance for Capital and Technology’s IMPACT conference this week. The company is finishing off pre-clinical studies in the r... |
| Jun 10, 2010 | Quark Pharmaceuticals Closes $10M Financing Round | Quark Pharmaceuticals, Inc., a Fremont, California-based developer of RNAi-based therapeutics, closed a $10m financing round. Investors include Japan-based SBI Holdings Group. In conjunction with the round, Mr. Yoshitaka Kitao and Mr. Rober... |
| Apr 7, 2008 | Life-science briefing: Monday, April 7, 2008 | TODAY’S HEADLINES: Quark Pharma gets $27M for RNAi drugs (release) TargetRx takes in $9.6M for physician-prescribing data (release) D-Pharm raises more than $3M for fat-like drugs (release) Vortex Medical raises $2.3M for medical devices (V... |
| Feb 18, 2008 | Quark Pharma: Not quite such a chameleon, after all | Last June, I posted about the long and winding history of Fremont, Calif.-based Quark Pharmaceuticals, a biotech developing drugs based on a new gene-silencing technology called RNA interference, or RNAi. At the time, I labeled the company ... |
| Jul 30, 2007 | Quark Pharma withdraws its long-shot IPO | Quark Pharmaceuticals, the biotech chameleon that tried to portray itself as a hot new RNAi company, has withdrawn its IPO. The company said that “the terms currently obtainable in the public marketplace are not sufficiently attractive” to ... |
| Jun 6, 2007 | Biotech chameleons: Quark Pharma aims for $81M IPO | (UPDATED: See below.) For some reason, biotechnology is rife with chameleons — companies that suddenly and radically alter their scientific strategy, disease focus or business model, sometimes to recover from a major failure, and sometimes ... |
| Angion’s kidney therapy advances | Angion Biomedica announced positive phase II clinical trial results for its drug ANG-3777, which treats acute kidney injuries. The study tested whether the small molecule could help kidney transplant patients suffering from delayed graft fu... | |
| Rival’s setback provides unexpected advantage for drug developer’s kidney injury therapeutic | Frequently, the path to commercial approval for a biopharmaceutical startup’s drug is filled with adversity. But the drug development industry is also filled with unexpected twists. Last month, Pittsburgh-based Complexa unexpectedly lost a ... |